Psychopharmacology_tips - Articles - Page 3

Non-Addictive, Pharmacological Options for Sleep

August 23, 2018

Daniel Carlat, MD Publisher, The Carlat Addiction Treatment Report Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this month’s interview with Dr. Eric Hermes, we learned about his approach to treating insomnia in patients with substance use disorders, with a focus on cognitive behavioral therapy. In this article, we’ll look at some non-addictive pharmacological options.

Is Varenicline Effective for Alcohol Use Disorder?

May 1, 2018

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Acting on the nicotinic acetylcholine receptors, varenicline (Chantix) is an FDA-approved treatment for smoking cessation. These receptors are implicated in both nicotine and alcohol reward pathways, so could varenicline also be helpful for treating alcohol use disorder (AUD)?

Youth, Antidepressant Medications, and Type 2 Diabetes

May 1, 2018

Adam Strassberg, MD.

Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Over the last decade, several published studies have reported an increased risk of type 2 diabetes associated with antidepressant use in adults. But does the same hold true for children and adolescents?

Guidelines for Switching From Methadone to Buprenorphine

May 1, 2018

Rehan Aziz, MD.

Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Recent guidelines published by the American Society of Addiction Medicine and nationally in Australia provide support for transferring patients from methadone to buprenorphine-naloxone (BNX). Patients may switch, thinking BNX is easier to discontinue or because of methadone side effects.

Lithium: Practical Considerations for Children With Suicidal Thinking

January 1, 2018

Eve Dreyfus, MD and Joshua Feder, MD

Eve Dreyfus, MD Pediatric psychiatrist for Beacon Medical Group Behavioral Health, South Bend, IN Dr. Dreyfus has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Josh Feder, MD Editor-in-chief of The Carlat Child Psychiatry Report Dr. Feder has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This article covers the judicious consideration and use of lithium in children with suicidal thinking and behavior as part of their overall mental health picture. These challenging situations demand that we stay calm and remain receptive to the frustrations of the family, while at the same time addressing the child’s difficulties.

Evidence Behind Aripiprazole for the Treatment of Tourette’s Disorder

January 1, 2018

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Tourette’s disorder (TD) is a movement disorder emerging during childhood that causes persistent motor and vocal tics. TD is treated with a variety of medications, but often with an off-label designation.

Psychopharmacology for Patients With Intellectual Disability

September 1, 2017

Julie Gentile, MD and David Dixon, DO

Julie Gentile, MD Professor of psychiatry at the Boonshoft School of Medicine, Wright State University. Project director for Ohio’s Coordinating Center of Excellence in Mental Illness & Intellectual Disability. Dr. Gentile has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. David Dixon, DO Clinical chief resident, Wright State University, Department of Psychiatry. Dr. Dixon has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prescribing psychotropic medications in patients with intellectual disability (ID) requires certain nuances in approach that may be unfamiliar to some psychiatrists. In this article, we’ll discuss some aspects of assessment and treatment that you may find useful when you encounter and work with such patients.

Interviewing and Evaluating Patients With Intellectual Disability

September 1, 2017

Julie Gentile, MD

Julie Gentile, MD Professor of psychiatry at the Boonshoft School of Medicine, Wright State University. Project director for Ohio’s Coordinating Center of Excellence in Mental Illness & Intellectual Disability Dr. Gentile has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychotherapy is all about communicating, yet people with intellectual disability often have significant limitations in their communication skills, depending on their level of cognitive functioning. Is it possible for us to help these patients? If so, how? Julie Gentile, MD (www.juliegentile.com) has been looking at these questions for 20 years.

Helping People With Co-Occurring Mental Health and Substance Use Disorders

August 1, 2017

Kenneth Minkoff, MD

Kenneth Minkoff, MD Senior system consultant, ZiaPartners, Inc, which provides consulting services for co-occurring disorders. Part-time assistant professor of psychiatry at Harvard Medical School. Dr. Minkoff has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Patients with co-occurring disorders (COD, also known as “dual diagnosis”) are often regarded as among the most challenging patients to treat. You need to track two conditions that interact in unpredictable ways, with patients who may not be inclined to follow your recommendations. It’s no surprise that such patients typically have poorer outcomes than those with either disorder in isolation. And these patients are far from rare.

Take The CME Post-Test for Dual Diagnosis, CATR, August 2017

August 1, 2017

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit.